FDA (FDA) News
Track canonical SquawkNews coverage tagged to FDA, FDA. This hub brings together deduplicated headlines about nasdaqgs, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 9 indexed stories across 3 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
OS Therapies Third Quarter 2026 Corporate Outlook
Upcoming Type B Statistical Methods Meeting expected to set stage for FDA to align with EMA and MHRA on use of Fall 2026 3-year overall survival data combined with biomarkers to support early market access
REGULATION | Jul 06, 2026, 01:01 PM UTC
L
Splash Beverage Group Acquires Exclusive Global Rights to CannEpil®, an Epilepsy Therapy with Established European Patient Access, FDA Engag
FORT LAUDERDALE, Fla., July 06, 2026 (GLOBE NEWSWIRE) -- Splash Beverage Group, Inc. (NYSE A
REGULATION | Jul 06, 2026, 12:31 PM UTC
L
IceCure Highlights Expanding Commercial Adoption of ProSense™ Cryoablation in Brazil Following FDA Clearance for Breast Cancer
IceCure Highlights Expanding Commercial Adoption of Pro
REGULATION | Jul 06, 2026, 12:12 PM UTC
L
BetterLife Engages Nucro-Technics to Complete the last GLP Toxicology Study of BETR-001 Required by the FDA for IND and Phase 1
Vancouver, British Columbia--(. - July 6, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company") announces it has entered into an agreement with
REGULATION | Jul 06, 2026, 12:01 PM UTC
L
GuideAI Health Appoints Renowned Interventional Radiologist Dr. James Benenati to Advisory Board Following FDA 510(k) Clearance of VAOT
BOSTON, July 06, 2026 (GLOBE NEWSWIRE) -- GuideAI Health Corp. (Cboe CA: GDAI
REGULATION | Jul 06, 2026, 12:00 PM UTC
L
Pharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks
If approved, deucrictibant will be the first oral bradykinin B2 receptor antagonist to tre
REGULATION | Jul 06, 2026, 10:50 AM UTC
L
Ascletis Submits Two IND Applications to the U.S. FDA for the Treatment of Obesity: ASC36 Once-Monthly Injection, a Peptide Amylin Receptor
Ascletis Submits Two IND Applications to the U.S. FDA f
REGULATION | Jul 06, 2026, 01:11 AM UTC
M
FDA: Names 3 Finalists
Three finalists emerge to lead the FDA
REGULATION | Jun 26, 2026, 02:50 PM UTC
L
REGN - Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)
REGN - Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)
REGULATION | Jun 22, 2026, 11:00 AM UTC